NZ210501A
(en)
|
1983-12-13 |
1991-08-27 |
Kirin Amgen Inc |
Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
|
US4703008A
(en)
|
1983-12-13 |
1987-10-27 |
Kiren-Amgen, Inc. |
DNA sequences encoding erythropoietin
|
KR850004274A
(ko)
|
1983-12-13 |
1985-07-11 |
원본미기재 |
에리트로포이에틴의 제조방법
|
JP2983629B2
(ja)
|
1989-10-13 |
1999-11-29 |
キリン―アムジエン・インコーポレイテツド |
エリスロポエチンイソフォーム
|
US7217689B1
(en)
|
1989-10-13 |
2007-05-15 |
Amgen Inc. |
Glycosylation analogs of erythropoietin
|
US5856298A
(en)
|
1989-10-13 |
1999-01-05 |
Amgen Inc. |
Erythropoietin isoforms
|
IL192290A0
(en)
|
1993-08-17 |
2008-12-29 |
Kirin Amgen Inc |
Erythropoietin analogs
|
US6562596B1
(en)
|
1993-10-06 |
2003-05-13 |
Amgen Inc. |
Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
|
US5773569A
(en)
|
1993-11-19 |
1998-06-30 |
Affymax Technologies N.V. |
Compounds and peptides that bind to the erythropoietin receptor
|
US5830851A
(en)
|
1993-11-19 |
1998-11-03 |
Affymax Technologies N.V. |
Methods of administering peptides that bind to the erythropoietin receptor
|
US5885574A
(en)
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
ATE306930T1
(de)
|
1994-08-12 |
2005-11-15 |
Immunomedics Inc |
Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
US5767078A
(en)
|
1995-06-07 |
1998-06-16 |
Johnson; Dana L. |
Agonist peptide dimers
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
NZ502375A
(en)
|
1997-07-14 |
2001-11-30 |
Bolder Biotechnology Inc |
The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
|
PT986644E
(pt)
|
1997-07-23 |
2007-01-31 |
Roche Diagnostics Gmbh |
Preparação de eritropoietina por activação genética endógena com promotores virais
|
US6030086A
(en)
|
1998-03-02 |
2000-02-29 |
Becton, Dickinson And Company |
Flash tube reflector with arc guide
|
US6310078B1
(en)
|
1998-04-20 |
2001-10-30 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted amino acids as erythropoietin mimetics
|
ES2273497T3
(es)
|
1998-06-15 |
2007-05-01 |
Gtc Biotherapeutics, Inc. |
Proteina de fusion de la albumina serica humana de eritropoyetina analoga.
|
US20050181482A1
(en)
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
CN1810832B
(zh)
|
1998-10-23 |
2012-12-12 |
麒麟-安姆根有限公司 |
与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
|
AR020848A1
(es)
|
1998-10-23 |
2002-05-29 |
Amgen Inc |
Metodos y composiciones para la prevencion y el tratamiento de anemia
|
US6395511B1
(en)
|
1998-11-27 |
2002-05-28 |
Darwin Discovery, Ltd. |
Nucleic acids encoding a novel family of TGF-β binding proteins from humans
|
EP1006184A1
(fr)
|
1998-12-03 |
2000-06-07 |
F. Hoffmann-La Roche Ag |
Protéines interagissant avec le récepteur de IGF-1, gènes codant pour ces protéines et leurs utilisations
|
WO2000061637A1
(fr)
|
1999-04-14 |
2000-10-19 |
Smithkline Beecham Corporation |
Anticorps du recepteur d'erythropoietine
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
CZ299516B6
(cs)
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
JP2003512840A
(ja)
|
1999-10-22 |
2003-04-08 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
ラット脳に由来する核酸分子およびプログラム細胞死モデル
|
EP1228214A2
(fr)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Formes d'erythropoietine dotees de proprietes ameliorees
|
US20050202538A1
(en)
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
DE60107203T3
(de)
|
2000-01-21 |
2009-07-23 |
Biovex Ltd. |
Herpes-virusstämme für die gentherapie
|
AUPQ599700A0
(en)
|
2000-03-03 |
2000-03-23 |
Super Internet Site System Pty Ltd |
On-line geographical directory
|
US6586398B1
(en)
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
CA2406807C
(fr)
|
2000-04-21 |
2010-04-06 |
Amgen Inc. |
Methodes et compositions destinees a la prevention et au traitement de l'anemie
|
US6756480B2
(en)
|
2000-04-27 |
2004-06-29 |
Amgen Inc. |
Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
|
US7078376B1
(en)
|
2000-08-11 |
2006-07-18 |
Baxter Healthcare S.A. |
Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
|
RU2003109746A
(ru)
|
2000-09-08 |
2005-01-27 |
Грифон Терапьютикс, Инк. (Us) |
Синтетические белки, стимулирующие эритропоэз
|
US7271689B1
(en)
|
2000-11-22 |
2007-09-18 |
Fonar Corporation |
Magnet structure
|
ATE505204T1
(de)
|
2000-12-20 |
2011-04-15 |
Hoffmann La Roche |
Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
|
AR032028A1
(es)
|
2001-01-05 |
2003-10-22 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
JP2005503127A
(ja)
|
2001-04-04 |
2005-02-03 |
ジェンオディセ |
エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド
|
ES2527471T3
(es)
|
2001-05-11 |
2015-01-26 |
Amgen Inc. |
Péptidos y moléculas relacionadas que se unen a TALL-1
|
PL222211B1
(pl)
|
2001-06-26 |
2016-07-29 |
Amgen Fremont Inc |
Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
|
US6900292B2
(en)
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
US7247304B2
(en)
|
2001-08-23 |
2007-07-24 |
Genmab A/S |
Methods of treating using anti-IL-15 antibodies
|
JP4359503B2
(ja)
|
2001-08-23 |
2009-11-04 |
ゲンマブ エー/エス |
インターロイキン15(il−15)に特異的なヒト抗体
|
US6930086B2
(en)
|
2001-09-25 |
2005-08-16 |
Hoffmann-La Roche Inc. |
Diglycosylated erythropoietin
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
WO2003055526A2
(fr)
|
2001-12-21 |
2003-07-10 |
Maxygen Aps |
Conjugues d'erythropoietine
|
JP4606739B2
(ja)
|
2002-01-18 |
2011-01-05 |
ピエール、ファーブル、メディカマン |
新規抗igf−ir抗体およびその使用
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
GB0202252D0
(en)
|
2002-01-31 |
2002-03-20 |
Oxford Biomedica Ltd |
Anemia
|
WO2003064664A1
(fr)
|
2002-01-31 |
2003-08-07 |
Oxford Biomedica (Uk) Limited |
Vecteur d'expression de l'erythropoietine physiologiquement regule, destine au traitement de l'anemie
|
ATE363541T1
(de)
|
2002-03-26 |
2007-06-15 |
Lek Tovarna Farmacevtskih |
Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
|
EP1572079A4
(fr)
|
2002-03-29 |
2006-09-06 |
Centocor Inc |
Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
|
BRPI0308946B1
(pt)
|
2002-03-29 |
2016-08-30 |
Kumiai Chemical Industry Co |
ácido nucleico, proteína, vetor recombinante, bactéria, processos para cultivar planta que apresenta o referido ácido nucleico, para cultivar planta que apresenta a referida proteína, para seleção de célula transformante que apresenta o referido ácido nucleico e para selecionar célula transformante que apresenta a referida proteína
|
WO2003094858A2
(fr)
|
2002-05-13 |
2003-11-20 |
Modigenetech Ltd. |
Érythropoïétine comportant une extension ctp
|
WO2003100008A2
(fr)
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Anticorps anti-igfr humain neutralisant
|
US8034904B2
(en)
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
US7538195B2
(en)
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
KR20050033563A
(ko)
|
2002-06-28 |
2005-04-12 |
센토코 인코포레이티드 |
포유동물 epo 모방 ch1 결실된 모방체, 조성물, 방법및 용도
|
EP1545608A4
(fr)
|
2002-06-28 |
2006-09-13 |
Centocor Inc |
Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
|
WO2004009627A1
(fr)
|
2002-07-19 |
2004-01-29 |
Cangene Corporation |
Composes erythropoietiques pegyles
|
TW200413406A
(en)
|
2002-08-26 |
2004-08-01 |
Kirin Brewery |
Peptides and drugs containing the same
|
NZ593428A
(en)
|
2002-09-06 |
2013-01-25 |
Amgen Inc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
BR0314107A
(pt)
|
2002-09-11 |
2005-07-19 |
Fresenius Kabi De Gmbh |
Método de produção de derivados de hidroxialquil amido
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
TWI320716B
(en)
|
2002-10-14 |
2010-02-21 |
Abbott Lab |
Erythropoietin receptor binding antibodies
|
US20040071694A1
(en)
|
2002-10-14 |
2004-04-15 |
Devries Peter J. |
Erythropoietin receptor binding antibodies
|
US7396913B2
(en)
|
2002-10-14 |
2008-07-08 |
Abbott Laboratories |
Erythropoietin receptor binding antibodies
|
WO2004034988A2
(fr)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
|
US20040091961A1
(en)
|
2002-11-08 |
2004-05-13 |
Evans Glen A. |
Enhanced variants of erythropoietin and methods of use
|
KR20130036378A
(ko)
|
2002-12-20 |
2013-04-11 |
암겐 인코포레이티드 |
미오스타틴을 저해하는 결합제
|
EP1603948A1
(fr)
|
2003-03-14 |
2005-12-14 |
Pharmacia Corporation |
Anticorps specifiques du recepteur d'igf-i pour le traitement de cancers
|
JP4473257B2
(ja)
|
2003-04-02 |
2010-06-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
インスリン様成長因子i受容体に対する抗体及びその使用
|
US7220410B2
(en)
|
2003-04-18 |
2007-05-22 |
Galaxy Biotech, Llc |
Monoclonal antibodies to hepatocyte growth factor
|
WO2005016970A2
(fr)
|
2003-05-01 |
2005-02-24 |
Imclone Systems Incorporated |
Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
MXPA05012313A
(es)
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Peptidos que se unen al receptor de eritropoyetina.
|
ATE428727T1
(de)
|
2003-05-12 |
2009-05-15 |
Affymax Inc |
Neue, an den erythropoietinrezeptor bindende peptide
|
BRPI0411160A
(pt)
|
2003-05-12 |
2006-07-11 |
Affymax Inc |
novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
|
US7074755B2
(en)
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
KR20060032140A
(ko)
|
2003-05-30 |
2006-04-14 |
센토코 인코포레이티드 |
트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
|
US20050037390A1
(en)
|
2003-06-04 |
2005-02-17 |
Irm Llc, A Delaware Limited Liability Company |
Methods and compositions for modulating erythropoietin expression
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
NZ544751A
(en)
|
2003-07-15 |
2009-05-31 |
Amgen Inc |
Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
|
JP5105874B2
(ja)
|
2003-07-18 |
2012-12-26 |
アムジエン・インコーポレーテツド |
肝細胞増殖因子に対する特異的結合因子
|
US20050019914A1
(en)
|
2003-07-24 |
2005-01-27 |
Aventis Pharma Deutschland Gmbh |
Perfusion process for producing erythropoietin
|
GB0317511D0
(en)
|
2003-07-25 |
2003-08-27 |
Biovex Ltd |
Viral vectors
|
WO2005021579A2
(fr)
|
2003-08-28 |
2005-03-10 |
Biorexis Pharmaceutical Corporation |
Peptides mimetiques epo et proteines de fusion
|
BRPI0409650A
(pt)
|
2003-09-09 |
2006-04-25 |
Warren Pharmaceuticals Inc |
métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
|
JP4767857B2
(ja)
|
2003-09-30 |
2011-09-07 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ベンゾイミダゾール化合物
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
KR20060099520A
(ko)
*
|
2003-10-21 |
2006-09-19 |
노보 노르디스크 에이/에스 |
의료용 피부 장착 장치
|
AU2004290017B2
(en)
|
2003-11-07 |
2012-05-03 |
Immunex Corporation |
Antibodies that bind interleukin-4 receptor
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
EP1694347B1
(fr)
|
2003-11-24 |
2013-11-20 |
BioGeneriX AG |
Erythropoiétine glycopegylée
|
WO2005058967A2
(fr)
|
2003-12-16 |
2005-06-30 |
Pierre Fabre Medicament |
Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
|
EP1548031A1
(fr)
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Erythropoietin identique à la nature
|
JP2008500275A
(ja)
|
2003-12-31 |
2008-01-10 |
セントカー・インコーポレーテツド |
N末端の遊離チオールを有する新規な組み換えタンパク質
|
PT1699821E
(pt)
|
2003-12-31 |
2012-08-23 |
Merck Patent Gmbh |
Proteína de fusão fc-eritropoietina com farmacocinética melhorada
|
US7423139B2
(en)
|
2004-01-20 |
2008-09-09 |
Insight Biopharmaceuticals Ltd. |
High level expression of recombinant human erythropoietin having a modified 5′-UTR
|
US20050187158A1
(en)
|
2004-01-22 |
2005-08-25 |
Ranby Mats G. |
Pharmaceutical composition
|
WO2005084711A1
(fr)
|
2004-03-02 |
2005-09-15 |
Chengdu Institute Of Biological Products |
Erythropoietine recombinante pegylee a activite in vivo
|
WO2005092369A2
(fr)
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugues d'hydroxy-ethyl-amidon et d'erythropoietine
|
MXPA06010887A
(es)
|
2004-03-23 |
2007-03-08 |
Amgen Inc |
Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano.
|
US20050227289A1
(en)
|
2004-04-09 |
2005-10-13 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
CA2563874A1
(fr)
|
2004-04-23 |
2005-11-03 |
Cambridge Antibody Technology Limited |
Variants d'erythropoietine
|
BRPI0513029A
(pt)
|
2004-07-07 |
2008-04-22 |
Lundbeck & Co As H |
método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
|
FR2873699B1
(fr)
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
US20060073563A1
(en)
|
2004-09-02 |
2006-04-06 |
Xencor, Inc. |
Erythropoietin derivatives with altered immunogenicity
|
EP1812461A2
(fr)
|
2004-11-10 |
2007-08-01 |
AplaGen GmbH |
Molécules favorisant l'hématopoiese
|
US7648483B2
(en)
*
|
2004-11-22 |
2010-01-19 |
Intelliject, Inc. |
Devices, systems and methods for medicament delivery
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
WO2006081171A1
(fr)
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Anticorps anti-amyloide humanise
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
CN101613409B
(zh)
|
2005-06-17 |
2014-06-04 |
英克隆有限责任公司 |
抗-PDGFRα抗体
|
WO2007000328A1
(fr)
|
2005-06-27 |
2007-01-04 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
|
EP2388277A3
(fr)
|
2005-07-18 |
2013-03-20 |
Amgen, Inc |
Anticorps humains à neutralisation anti-B7RP1
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
PE20071101A1
(es)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
GB0603683D0
(en)
|
2006-02-23 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
EP2032600A2
(fr)
|
2006-05-19 |
2009-03-11 |
Glycofi, Inc. |
Compositions d'érythropoïétine
|
WO2007141210A1
(fr)
*
|
2006-06-06 |
2007-12-13 |
Novo Nordisk A/S |
Ensemble constitué d'un dispositif conçu pour être placé sur la peau et d'un emballage correspondant
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
CA2667989A1
(fr)
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonistes de pcsk9
|
EP2083859A4
(fr)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
Antagonistes de pcsk9
|
CA2667894A1
(fr)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonistes de pcsk9
|
EP2083860A4
(fr)
|
2006-11-07 |
2010-05-26 |
Merck Sharp & Dohme |
Antagonistes de pcsk9
|
EP2628752A1
(fr)
|
2006-12-14 |
2013-08-21 |
Merck Sharp & Dohme Corp. |
Anticorps anti-TSLP modifiés
|
AR066042A1
(es)
|
2007-04-13 |
2009-07-22 |
Novartis Ag |
Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
|
CA2691157A1
(fr)
|
2007-06-20 |
2008-12-24 |
Irm Llc |
Procedes et compositions pour traiter des maladies allergiques
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
US20130072665A1
(en)
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
WO2009055783A2
(fr)
|
2007-10-26 |
2009-04-30 |
Schering Corporation |
Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol
|
US8708961B2
(en)
*
|
2008-01-28 |
2014-04-29 |
Medsolve Technologies, Inc. |
Apparatus for infusing liquid to a body
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
WO2009131740A2
(fr)
|
2008-04-23 |
2009-10-29 |
Amgen Inc. |
Variants neutralisants de la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et ses applications
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
WO2010142813A1
(fr)
*
|
2009-06-12 |
2010-12-16 |
Novo Nordisk A/S |
Dispositif d'administration de médicament avec capuchon à fonctions pour ensemble aiguille
|
EP2480576A4
(fr)
|
2009-09-25 |
2013-04-10 |
Merck Sharp & Dohme |
Antagonistes de pcsk9
|
ES2732900T3
(es)
*
|
2009-10-13 |
2019-11-26 |
Valeritas Inc |
Dispositivo de administración de fluido
|
JP2013509194A
(ja)
|
2009-10-30 |
2013-03-14 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ax213およびax132pcsk9アンタゴニストおよびバリアント
|
EP2493505A4
(fr)
|
2009-10-30 |
2013-06-12 |
Merck Sharp & Dohme |
Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afférentes
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
US20110172645A1
(en)
*
|
2010-01-08 |
2011-07-14 |
Ratio, Inc. |
Wearable drug delivery device including integrated pumping and activation elements
|
US20120302844A1
(en)
*
|
2010-01-14 |
2012-11-29 |
Schnidrig Juerg |
Skin mounted medical patch device
|
WO2011111007A2
(fr)
|
2010-03-11 |
2011-09-15 |
Rinat Neuroscience Corporation |
Anticorps présentant une liaison à l'antigène dépendante du ph
|
EA032537B1
(ru)
|
2010-06-07 |
2019-06-28 |
Эмджен Инк. |
Способ работы устройства для доставки лекарственного средства
|
WO2012054438A1
(fr)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
MA34818B1
(fr)
|
2010-12-22 |
2014-01-02 |
Genentech Inc |
Anticorps anti-pcsk9 et procédés d'utilisation
|
WO2012101253A1
(fr)
|
2011-01-28 |
2012-08-02 |
Sanofi |
Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
|
CN103562227B
(zh)
|
2011-02-11 |
2016-12-21 |
诺瓦提斯公司 |
Pcsk9拮抗剂
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
JP6426107B2
(ja)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
Apj受容体アゴニストおよびその使用
|
JP2016513666A
(ja)
|
2013-03-14 |
2016-05-16 |
アムジエン・インコーポレーテツド |
組織メタロプロテイナーゼ阻害物質3型(timp−3)の変異体、組成物、及び方法
|
US20140274874A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
|
AU2014235430A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
US20150004174A1
(en)
|
2013-06-28 |
2015-01-01 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
WO2015095639A1
(fr)
*
|
2013-12-20 |
2015-06-25 |
Becton, Dickinson And Company |
Systèmes adhésifs pour set de perfusion
|
KR102506249B1
(ko)
|
2014-06-03 |
2023-03-03 |
암겐 인코포레이티드 |
약물 전달 시스템 및 사용 방법
|
CN107073205A
(zh)
*
|
2014-09-15 |
2017-08-18 |
赛诺菲 |
具有消毒垫的药剂输送装置
|
EP3193981B1
(fr)
*
|
2014-09-15 |
2020-11-04 |
Sanofi |
Dispositif d'administration de médicaments de type patch cutané avec mécanisme integré pour stériliser la peau
|
JOP20170042B1
(ar)
*
|
2016-02-12 |
2022-09-15 |
Amgen Inc |
وسيلة توصيل عقار، طريقة تصنيعه وطريقة استخدامه
|